NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) SEC filings

NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) SEC filings — 10-K, 10-Q, 8-K, and Form 4 as cached from EDGAR. When an exhibit lands, this page shows the headline, the numbers, and why it matters.

Those exhibit numbers sit next to the income-statement cache: Latest reported NAMS revenue for 2025-12-31 was $22.5M. Net income was -$203.8M. Revenue was down 50.6% from 2024-12-31 to 2025-12-31. NAMS currently screens at market cap $2.42B. The NAMS filings page is the source view; the stock page is the research view.

EDGAR remains the official archive. Lician caches 8-K exhibits so you can read what NewAmsterdam Pharma Company N.V. Ordinary Shares said without waiting on a live EDGAR scrape. Item 2.02 is the earnings exhibit — this page prefers EX-99.1 revenue, growth, EPS, and guidance over a form-type label. Form 4 insider prints stay on the same ticker timeline.